Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

NCT05482334 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05482334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05482334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Withdrawn
Start date
October 23, 2023
Completion date
September 30, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome